Welcome to our dedicated page for ORGANIGRAM GLOBAL SEC filings (Ticker: OGI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organigram Global Inc. filings document the disclosures of a Canadian cannabis company listed on Nasdaq and the TSX. Its Form 6-K reports furnish news releases, material change reports, shareholder meeting materials, proxy forms and other exhibits covering operating results, product announcements, material agreements and corporate events.
The company’s regulatory record includes disclosure about licensed cultivation and processing, adult-use cannabis brands, cannabinoid beverages, the FAST nanoemulsion technology platform, Health Canada regulation, capital-structure matters, shareholder voting, board and committee governance, and director and executive compensation practices.
Organigram Global Inc. (OGI) is accelerating integration of its acquired German business, Sanity Group GmbH, moving from a standalone structure to a unified global operating model. Sanity contributed approximately CAD$40 million to consolidated net revenue in the most recent quarter, representing over 35% of net revenue, and was accretive to Adjusted EBITDA. Sanity’s quarterly revenue has increased 34% since December 31, 2025 to €25.5 million, underscoring its importance within Organigram’s portfolio.
The company amended the Sanity acquisition agreement, replacing the performance-based earnout with a fixed earnout set at 85% of the original maximum. The earnout will comprise €20 million in cash plus approximately €76 million in Organigram shares, determined using a 20-day VWAP with a floor of C$3.00 and cap of C$4.00 per share. The earnout becomes payable as of April 1, 2027, with payment and share issuance to occur no later than May 1, 2027. New leadership roles were created, including President, Rest of World & Chief Strategy Officer and Global Chief Operating Officer, to drive integration and international expansion across Canada, Germany and other key markets.
Organigram Global Inc. reported strong Q3 Fiscal 2026 results, with net revenue of $105,782, up 49% from Q3 2025, driven mainly by the April acquisition of Germany-based Sanity Group and higher Canadian recreational sales. Gross margin before fair value adjustments improved to 37% of net revenue from 32%, and adjusted EBITDA rose to $13,413 from $5,694.
The company recorded Q3 net income of $105,538, largely due to a $105,783 fair value gain on Preferred Shares linked to British American Tobacco’s investment, rather than core operations. Year-to-date net revenue reached $229,114 (up 28%) and net income $124,586. Cash and short-term investments declined to $11,667 as of June 30, 2026, reflecting the €107.3 million Sanity acquisition and higher working capital, partly funded by a BAT private placement and a new C$60 million credit facility. Management still expects Fiscal 2026 net revenue to exceed $350 million but now guides to modestly negative free cash flow for the year and continues to report a material weakness in internal controls over financial reporting.
Organigram Global Inc. will report earnings results for its third quarter ended June 30, 2026 on Tuesday, August 11, 2026, prior to market open. The company will host a conference call at 8:00 am Eastern Time, with registration and webcast access provided via online links and a replay available within 24 hours for 90 days.
Organigram is described as Canada's #1 cannabis company by market share and a growing global cannabis platform following its acquisition of Sanity Group GmbH. It operates cultivation, processing and edibles facilities in New Brunswick, Quebec, Manitoba and Southwestern Ontario, and markets multiple cannabis brands in Canada and Europe under Health Canada regulation.
Organigram Global Inc., which describes itself as Canada’s #1 cannabis company by market share, provides an update on integration of its recently acquired Sanity Group GmbH and its Canadian market position. Management states that the first quarter including Sanity will begin to show the financial contribution from its international business.
Since closing the acquisition on April 15, 2026, Sanity has maintained an average ~10% market share in Germany, broadly in line with revenue expectations. Recently announced German regulatory changes affecting medical cannabis reimbursement are not expected to be material, as reimbursement-based sales account for about 1% of Sanity’s revenue.
In Canada, Organigram reports leading category positions: 12.5% share in flower, 14.5% in vapes, and 7.3% in pre-rolls, categories that together represent more than 86% of national recreational cannabis retail sales. Overall Canadian recreational market share was 11.1% at the end of June, a 0.4 percentage point decline year-over-year but a 100 basis point increase versus May, helped by gains in beverages and concentrates. The company plans to report Q3 fiscal 2026 results on or about August 11, 2026 and to host a detailed digital investor session in late September.
Organigram Global Inc. reported Q2 Fiscal 2026 net revenue of $59,794, down 9% from Q2 Fiscal 2025 as recreational cannabis sales fell. Gross margin before fair value adjustments declined to 25% and adjusted EBITDA dropped to $870, reflecting weaker product mix and higher returns provisions. The quarter swung to a net loss of $921 versus prior-year net income of $42,456, driven mainly by smaller fair value gains on derivatives and a $5,800 impairment on its U.S. hemp-derived products business.
For the six months ended March 31, 2026, net revenue rose 14% to $123,332, with adjusted gross margin improving to 34% and net income at $19,048. Organigram closed the acquisition of German operator Sanity Group in April 2026 for upfront consideration of €107.3 million and updated Fiscal 2026 guidance, now projecting net revenue to exceed $350 million, with adjusted EBITDA and adjusted gross margin expected to surpass Fiscal 2025 levels and free cash flow around break even. The company highlights strong international expansion, including Germany and Australia, but faces regulatory headwinds for U.S. hemp-derived THC products and continues to remediate a material weakness in internal controls over financial reporting.
Organigram Global Inc. will release its second quarter fiscal 2026 results for the period ended March 31, 2026 on Tuesday, May 12, 2026, prior to market open. The company will hold a conference call that day at 8:00 a.m. Eastern Time, with advance registration required through online links.
Organigram describes itself as a leading Canadian cannabis company focused on high-quality products for adult consumers and international partnerships. It operates cultivation, processing, edibles and fulfillment facilities across multiple Canadian provinces and markets a portfolio of brands including Edison, SHRED, Big Bag O’ Buds and others.
Organigram Global Inc. saw its strategic investor BT DE Investments Inc., an affiliate of British American Tobacco, update its ownership position through an amended Schedule 13D. As of April 15, 2026, the investor beneficially owned 42,231,089 Common Shares, representing 29.9% of the outstanding Common Shares, plus 50,673,288 Class A preferred shares, all on a non-diluted basis.
The change reflects completion of Organigram’s acquisition of Sanity Group GmbH and a concurrent private placement. BT DE received Common and Preferred Shares as consideration for its Sanity stake and purchased additional Shares in a private placement, including via top-up rights. The Preferred Shares are non-voting, convertible into Common Shares subject to ownership caps. Under an updated investor rights agreement, the investor can nominate up to 30% of Organigram’s board and retains pre-emptive, top-up and registration rights as long as certain ownership thresholds are maintained.
Organigram Global Inc. has closed its previously announced acquisition of Germany-based Sanity Group, paying upfront consideration of €107.3 million, split between €78.0 million in cash and €29.3 million in shares. Sellers may receive up to an additional €113.8 million in earnout consideration tied to Sanity’s financial performance for the 12-month period ending April 1, 2027.
To help fund the deal, Organigram completed a private placement with British American Tobacco’s subsidiary for total gross proceeds of about C$65.2 million and secured new senior secured credit facilities of up to C$60 million, including a C$20 million term loan initially drawn. The transaction expands Organigram’s presence across key European cannabis markets and adds a new Sanity executive, Max Konrad Narr, to its board during the earnout period.
Organigram Global Inc. reported that shareholders overwhelmingly approved its planned acquisition of Sanity Group GmbH and a related private placement with a BAT subsidiary. The transaction resolution, which allows the indirect acquisition of all remaining Sanity shares and the issuance of up to 96,287,602 common shares, received 93% support from disinterested shareholders at the March 30, 2026 meeting.
The company describes the deal as financially accretive, noting that Sanity generated positive EBITDA in 2025 and will strengthen Organigram’s leadership in the global cannabis market, including a major presence in Germany. All ten director nominees were elected with roughly 98% support, PricewaterhouseCoopers LLP was reappointed as auditor with 97.1% support, and unallocated awards under the long‑term equity incentive plan were approved with 93.6% support. Closing of the Sanity transaction, expected in April 2026, remains subject to customary conditions, including completion of the private placement and senior secured credit facilities.
Organigram Global Inc. is advancing its proposed acquisition of German cannabis company Sanity Group GmbH after proxy advisor ISS recommended shareholders vote FOR the transaction resolution. ISS cited compelling strategic benefits, including greater scale, geographic diversification, stronger market presence, balance sheet and cash flow.
Under the agreement, Sanity shareholders will receive cash and Organigram shares with a deemed value of C$3.00 per share, representing a 71.4% premium to the closing TSX price on the last unaffected trading date. Total upfront consideration is €113.4 million, comprising €80.0 million in cash and €33.4 million in shares, plus potential earn-out payments of up to €113.8 million based on Sanity’s performance in the 12 months after closing.
The independent members of Organigram’s board unanimously support the deal and recommend shareholders vote FOR at the Annual General and Special Meeting on March 30, 2026, where routine items such as director elections, auditor appointment and equity plan approvals will also be considered.